<DOC>
	<DOC>NCT01878474</DOC>
	<brief_summary>The purpose of this study is to assess the safety and tolerability of single doses of TA-8995 in healthy Caucasian and Japanese volunteers.</brief_summary>
	<brief_title>Evaluation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TA-8995 With Single, Escalating Doses in Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Dyslipidemias</mesh_term>
	<criteria>Caucasian men aged 1855 years and ≥65 years Women of nonchildbearing potential Japanese men aged 1855 years Subjects were deemed healthy on the basis of medical history, physical examination, Electrocardiogram (ECG), vital signs and safety tests of blood and urine Subjects were able to give fully informed written consent HDLC level ≥2.59 mmol/L Abnormal Holter ECG Family history of long QT syndrome, hypokalaemia or Torsade de Pointes Vital signs or 12lead ECG values outside the acceptable range Positive tests for hepatitis B and C, HIV 1 and 2 Positive urine pregnancy test (women only) Severe adverse reaction or allergy to any drug Drug or alcohol abuse Smoking within the 6 months before dosing with TA8995 (Caucasian subjects), or smoking more than 10 cigarettes daily (Japanese subjects) Overthecounter or prescribed medication up to 7 days or 5 halflives (whichever was longer) before dosing with TA8995 Consuming food or drinks containing grapefruit or cranberry within the 7 days before dosing Participation in other clinical trials, or loss of more than 450 mL blood within the previous 3 months Clinically relevant abnormal findings at the screening assessment Clinically relevant abnormal medical history or concurrent medical condition Possibility that volunteer would not cooperate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>MT-8995</keyword>
	<keyword>Dyslipidemia</keyword>
	<keyword>Cholesteryl ester transfer proteins</keyword>
</DOC>